Browse studies

Find your next paid study

27,293 recruiting studies available now

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept wo…

Myelodysplastic Syndromes

Estimated

~$50 – $2,250

Actual pay is set by the research site.

TakedaNCT06499285

Phase 2

Propranolol With Definitive or Neoadjuvant Chemotherapy, Chemotherapy-Immunotherapy or Chemoradiation Therapy or Chemoradiation for Esophageal Adenocarcinoma A Phase II Study

This phase II trial studies the side effects and best dose of propranolol when administered concurrently with SOC neoadjuvant CRT in patients with esophageal c…

Esophageal Adenocarcinoma

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Roswell Park Cancer InstituteNCT04682158

Prospective Registry-Based Study Evaluating the Effectiveness and Safety of Odevixibat in Participants With Alagille Syndrome (ALGS)

This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives. Odevixibat is a medicine…

Alagille Syndrome

Estimated

~$10 – $1,125

Actual pay is set by the research site.

IpsenNCT06850038

Phase 3

A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 Days to Less Than 18 Years of Age With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

To evaluate the pharmacodynamics and safety of tolvaptan in pediatric subjects with ARPKD

Autosomal Recessive Polycystic Kidney (ARPKD)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04782258

Observational

Use of the Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States

Background: Eosinophilic esophagitis (EoE) is a disease that causes inflammation in the esophagus. The esophagus is the tube that moves food from the mouth to…

DysphagiaEosinophilic Esophagitis

Estimated

~$10 – $675

Actual pay is set by the research site.

National Institute of Allergy and Infectious Diseases (NIAID)NCT07027826

Phase 1

An Open-label, Multicenter Phase 1b/2 Study to Evaluate the Safety and Efficacy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line …

B-cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Nurix Therapeutics, Inc.NCT07520006

Phase 3

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis

The purpose of this study is to find out how well and safely elafibranor works compared to placebo in adult participants with Primary sclerosing cholangitis (P…

Primary Sclerosing Cholangitis

Estimated

~$50 – $2,250

Actual pay is set by the research site.

IpsenNCT07387549

Observational

A Clinician-Patient Dual Behavior Change Framework to Leverage Informed Digital Nudges to Reduce Hospital Readmissions and Improve Patient Outcomes: A Randomized Trial for Scalable Strategy to Reduce Readmissions (PREVENT-R)

The PREVENT-R trial will evaluate an intervention targeting both clinician and patient behavior. The clinician-focused piece consists of an electronic medical …

ReadmissionReadmission RatesReadmission, Hospital+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Yale UniversityNCT07890961

Phase 3

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants With Primary IgA Nephropathy in Combination With Stable Background Therapy

Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that b…

Kidney Disease

Estimated

~$50 – $2,250

Actual pay is set by the research site.

TakedaNCT06963827

Phase 3

A Phase 3, Randomized, Double-blind, Active-control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients With Myelofibrosis Who Are JAK Inhibitor Naive

The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxo…

Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Novartis PharmaceuticalsNCT07357727

Clinical Study Protocol SGi 1.0 + EPW 1.0 + Compatible Clinical Displays Clinical Validation Study

The primary objective of this study is to show safety and effectiveness of the investigational device for In Vitro Diagnostic (IVD) use as an aid to the pathol…

Pathological Processes

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Philips Digital & Computational PathologyNCT07881874

Observational

Plasma Lipids-dependent Vitamin E Metabolism During Dynamic Hyperlipidemia

Background: Obesity is known to lead to diseases such as diabetes and high cholesterol (or fats) in the blood (hyperlipidemia). But no one knows why. Research…

Lipid Metabolism Disorders

Estimated

~$10 – $675

Actual pay is set by the research site.

National Heart, Lung, and Blood Institute (NHLBI)NCT07715890